skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
HDAC Inhibitor CHR-2845 (Code C82690)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: HDAC Inhibitor CHR-2845

Definition: A hydroxamic acid-derived histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. CHR-2845 inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in chromatin remodeling, inhibition of tumor oncogene transcription, inhibition of tumor cell division, and the induction of tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins; this agent may specifically target HDACs in cells of the monocyte-macrophage lineage.

Label: HDAC Inhibitor CHR-2845

NCI Thesaurus Code: C82690 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2830214  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
HDAC Inhibitor CHR-2845
Histone Deacetylase Inhibitor CHR-2845

External Source Codes: 
PDQ Closed Trial Search ID 633696
PDQ Open Trial Search ID 633696 (check for NCI PDQ open clinical trial info)
UMLS CUI C2830214

Other Properties:
     Name Value (qualifiers indented underneath)
code C82690
Legacy_Concept_Name HDAC_Inhibitor_CHR-2845
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom